Indira D Adapa, MD
Psychiatry · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Mental Health Systems Inc · Bio-Behavioral Medical Clinics, Inc
Hospitals listed: Community Regional Medical Center · Saint Agnes Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Adapa’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A86927 · Current
Licensed to practise in California · since 2004 · expires 2027-11-30 · University of Health Sciences, Vijayawada, Guntur Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
- Saint Agnes Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.312, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.141, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Saint Agnes Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.312 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.141 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.18 to 1.94) · 2,342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 197.82 (152.64 to 243.01) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 300 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 768 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 969 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 4,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 11,641 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 12,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.76 (2.91 to 6.61) · 2,466 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.49) · 864 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.61 (0.26 to 2.96) · 2,362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.1 (5.39 to 14.81) · 900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.4 (1.2 to 7.59) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.41 to 3.27) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.14 to 1.19) · 9,626 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 58 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.835 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.004 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,002 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 28.8 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.5 · 894 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.8 · 981 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 1,061 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.4 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 412 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.6 to 15.9) · 1,324 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 863 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 32% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$43,314
Medicare paid this office $43,314 for 100 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 31 | $13,807 | $92 |
| Psychotherapy with evaluation and management visit, 45 minutes | 13 | $6,234 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $5,397 | $132 |
| Psychotherapy with evaluation and management visit, 45 minutes | 40 | $4,739 | $63 |
| New patient visit (60+ min) | 24 | $3,487 | $145 |
See all 7 services
| Return visit (30+ min) | 31 | $13,807 | $92 |
| Psychotherapy with evaluation and management visit, 45 minutes | 13 | $6,234 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $5,397 | $132 |
| Psychotherapy with evaluation and management visit, 45 minutes | 40 | $4,739 | $63 |
| New patient visit (60+ min) | 24 | $3,487 | $145 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,241 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,965 | $61 |
Who their Medicare patients are
100 Original Medicare patients in 2024. Average age 66 · Under 65 36% · Women 45% · Also on Medicaid 73% · Health risk score 2.07. Above the middle of the specialty; the typical psychiatry clinician is at 1.35.
Conditions among them: High blood pressure 75% · Diabetes 55% · Depression 53% · Coronary heart disease 38% · Chronic kidney disease 33% · Heart failure 31% · Dementia 30% · Atrial fibrillation 24% · COPD 22% · Stroke 15% · Cancer 12%.
The office billed $83,816, Medicare allowed $57,339 and paid $43,314; for 505 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 100 | 505 | 66 | 2.07 | $83,816 | $43,314 |
| 2023 | 79 | 442 | 64 | 1.44 | $66,390 | $33,342 |
| 2022 | 120 | 601 | 64 | 1.65 | $93,794 | $47,716 |
| 2021 | 142 | 708 | 67 | 2.06 | $119,300 | $60,814 |
| 2020 | 171 | 698 | 68 | 2.17 | $117,768 | $59,355 |
| 2019 | 137 | 455 | 67 | 1.95 | $62,985 | $36,885 |
| 2018 | 130 | 516 | 65 | 2.54 | $55,838 | $37,872 |
| 2017 | 119 | 631 | 65 | 2.00 | $65,860 | $43,560 |
| 2016 | 152 | 578 | 60 | 2.09 | $62,756 | $41,732 |
| 2015 | 106 | 528 | 62 | 1.98 | $56,865 | $38,538 |
| 2014 | 132 | 530 | 65 | 2.03 | $59,950 | $42,667 |
| 2013 | 122 | 415 | 61 | 1.92 | $46,543 | $30,416 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 26 | $10,032 | $97 |
| Psychotherapy with evaluation and management visit, 45 minutes | 16 | $5,268 | $70 |
| Psychotherapy with evaluation and management visit, 45 minutes | 27 | $4,313 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $4,062 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $3,887 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,962 | $63 |
2022: 6 services
| Return visit (30+ min) | 24 | $13,139 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 52 | $8,567 | $159 |
| Psychotherapy with evaluation and management visit, 45 minutes | 20 | $8,366 | $70 |
| Psychotherapy with evaluation and management visit, 45 minutes | 52 | $6,466 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $3,940 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $3,892 | $57 |
2021: 6 services
| Return visit (30+ min) | 28 | $13,388 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 78 | $13,281 | $162 |
| Psychotherapy with evaluation and management visit, 45 minutes | 81 | $10,296 | $65 |
| Psychotherapy with evaluation and management visit, 45 minutes | 20 | $8,448 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $6,720 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $4,034 | $57 |
2020: 6 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 111 | $18,496 | $155 |
| Psychotherapy with evaluation and management visit, 45 minutes | 111 | $12,299 | $68 |
| Return visit (30+ min) | 22 | $8,715 | $85 |
| Psychotherapy with evaluation and management visit, 45 minutes | 22 | $7,535 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $5,582 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $3,459 | $59 |
2019: 8 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 62 | $10,778 | $159 |
| Return visit (30+ min) | 22 | $5,954 | $82 |
| Psychotherapy with evaluation and management visit, 45 minutes | 62 | $4,853 | $55 |
| Psychotherapy with evaluation and management visit, 45 minutes | 33 | $4,496 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,932 | $59 |
| New patient visit (60+ min) | 12 | $2,014 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,872 | $78 |
| Psychiatric diagnostic evaluation with medical services | 11 | $1,379 | $125 |
2018: 6 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 70 | $11,507 | $155 |
| Return visit (30+ min) | 20 | $9,539 | $82 |
| Psychotherapy with evaluation and management visit, 45 minutes | 28 | $5,301 | $42 |
| Psychotherapy with evaluation and management visit, 45 minutes | 68 | $3,757 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $3,054 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,703 | $74 |
2017: 6 services
| Return visit (30+ min) | 25 | $14,646 | $80 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $10,075 | $157 |
| Psychotherapy with evaluation and management visit, 45 minutes | 28 | $7,903 | $40 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,358 | $55 |
| Psychotherapy with evaluation and management visit, 45 minutes | 58 | $3,339 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,387 | $73 |
2016: 6 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 72 | $12,212 | $161 |
| Return visit (30+ min) | 21 | $10,141 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 59 | $6,849 | $54 |
| Psychotherapy with evaluation and management visit, 45 minutes | 31 | $5,898 | $41 |
| Psychotherapy with evaluation and management visit, 45 minutes | 54 | $2,846 | $43 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,642 | $103 |
2015: 7 services
| Return visit (30+ min) | 21 | $10,728 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 59 | $10,635 | $159 |
| Psychotherapy with evaluation and management visit, 45 minutes | 23 | $6,042 | $41 |
| Psychotherapy with evaluation and management visit, 45 minutes | 55 | $3,881 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,349 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,936 | $74 |
| New patient visit (60+ min) | 12 | $1,896 | $158 |
2014: 7 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 99 | $17,840 | $161 |
| Psychotherapy with evaluation and management visit, 45 minutes | 97 | $6,296 | $43 |
| Return visit (30+ min) | 13 | $6,149 | $83 |
| Psychotherapy with evaluation and management visit, 45 minutes | 17 | $3,556 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $2,979 | $74 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,211 | $55 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,661 | $111 |
2013: 7 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 77 | $12,019 | $154 |
| Return visit (30+ min) | 11 | $3,661 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $3,563 | $56 |
| Psychotherapy with evaluation and management visit, 45 minutes | 48 | $2,896 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $2,316 | $75 |
| Psychotherapy with evaluation and management visit, 45 minutes | 16 | $1,946 | $34 |
| Psychotherapy with evaluation and management visit, 1 hour | 21 | $1,409 | $67 |
Drugs they prescribed that Part D paid
$211,291
Pharmacies billed $211,291 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 414) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
317 generic and 97 brand-name prescriptions · $211,291 in drug cost · 55 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Invega Sustenna | 41 | $111,612 | $2,722 |
| Abilify Maintena | 28 | $61,659 | $2,202 |
| Trintellix | 14 | $9,637 | $688 |
| Lurasidone | 11 | $3,197 | $291 |
| Aripiprazole | 24 | $897 | $37 |
See all 15 drugs
| Invega Sustenna | 41 | $111,612 | $2,722 |
| Abilify Maintena | 28 | $61,659 | $2,202 |
| Trintellix | 14 | $9,637 | $688 |
| Lurasidone | 11 | $3,197 | $291 |
| Aripiprazole | 24 | $897 | $37 |
| Olanzapine | 34 | $506 | $15 |
| Sertraline | 72 | $497 | $7 |
| Divalproex | 19 | $343 | $18 |
| Mirtazapine | 17 | $259 | $15 |
| Escitalopram | 25 | $189 | $8 |
| Buspirone | 31 | $176 | $6 |
| Venlafaxine Hcl Er | 19 | $172 | $9 |
| Bupropion Xl | 11 | $159 | $14 |
| Risperidone | 13 | $148 | $11 |
| Trazodone | 15 | $133 | $9 |
Year by year
| 2024 | 414 | 53 | 0% (0) | 23% | $211,291 |
| 2023 | 397 | 53 | 0% (0) | 12% | $114,118 |
| 2022 | 497 | 61 | 0% (0) | 8% | $104,342 |
| 2021 | 503 | 60 | 0% (0) | 10% | $168,133 |
| 2020 | 434 | 62 | 0% (0) | 9% | $152,404 |
| 2019 | 439 | 68 | 0% (0) | 11% | $116,915 |
| 2018 | 428 | 63 | 0% (0) | 14% | $167,732 |
| 2017 | 402 | 44 | 0% (0) | 10% | $79,715 |
| 2016 | 355 | 36 | 0% (0) | 14% | $41,934 |
| 2015 | 262 | 41 | None | 23% | $26,628 |
| 2014 | 188 | 24 | 0% (0) | 28% | $18,648 |
| 2013 | 77 | 18 | 0% (0) | 31% | $6,260 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Abilify Maintena | 21 | $49,211 | $2,343 |
| Invega Sustenna | 14 | $27,351 | $1,954 |
| Aripiprazole | 22 | $2,282 | $104 |
| Sertraline | 91 | $1,212 | $13 |
| Mirtazapine | 23 | $942 | $41 |
| Risperidone | 37 | $648 | $18 |
| Olanzapine | 20 | $575 | $29 |
| Fluoxetine | 22 | $419 | $19 |
| Divalproex | 16 | $401 | $25 |
| Buspirone | 20 | $366 | $18 |
| Venlafaxine Hcl Er | 28 | $333 | $12 |
| Escitalopram | 20 | $251 | $13 |
| Bupropion Xl | 18 | $181 | $10 |
2022: 11 drugs
| Invega Sustenna | 12 | $26,171 | $2,181 |
| Mirtazapine | 48 | $1,135 | $24 |
| Aripiprazole | 12 | $1,061 | $88 |
| Divalproex Sodium Er | 16 | $990 | $62 |
| Sertraline | 98 | $665 | $7 |
| Venlafaxine Hcl Er | 24 | $572 | $24 |
| Escitalopram | 33 | $244 | $7 |
| Buspirone | 29 | $235 | $8 |
| Fluoxetine | 49 | $181 | $4 |
| Risperidone | 44 | $180 | $4 |
| Hydroxyzine | 13 | $68 | $5 |
2021: 15 drugs
| Ingrezza | 12 | $82,823 | $6,902 |
| Invega Sustenna | 12 | $19,896 | $1,658 |
| Trintellix | 25 | $11,197 | $448 |
| Mirtazapine | 65 | $1,478 | $23 |
| Sertraline | 93 | $741 | $8 |
| Venlafaxine Hcl Er | 31 | $622 | $20 |
| Bupropion Xl | 12 | $589 | $49 |
| Aripiprazole | 13 | $350 | $27 |
| Donepezil | 14 | $283 | $20 |
| Escitalopram | 38 | $265 | $7 |
| Duloxetine | 24 | $190 | $8 |
| Trazodone | 30 | $185 | $6 |
| Buspirone | 23 | $165 | $7 |
| Risperidone | 25 | $163 | $7 |
| Fluoxetine | 24 | $91 | $4 |
2020: 12 drugs
| Ingrezza | 13 | $87,053 | $6,696 |
| Trintellix | 25 | $15,618 | $625 |
| Mirtazapine | 57 | $827 | $15 |
| Sertraline | 90 | $699 | $8 |
| Aripiprazole | 20 | $552 | $28 |
| Venlafaxine Hcl Er | 32 | $497 | $16 |
| Bupropion Xl | 16 | $295 | $18 |
| Risperidone | 29 | $208 | $7 |
| Escitalopram | 29 | $192 | $7 |
| Trazodone | 30 | $177 | $6 |
| Buspirone | 16 | $161 | $10 |
| Lamotrigine | 17 | $144 | $8 |
2019: 13 drugs
| Ingrezza | 12 | $78,577 | $6,548 |
| Latuda | 12 | $15,603 | $1,300 |
| Trintellix | 17 | $7,861 | $462 |
| Sertraline | 101 | $646 | $6 |
| Mirtazapine | 37 | $513 | $14 |
| Venlafaxine Hcl Er | 25 | $389 | $16 |
| Bupropion Xl | 16 | $300 | $19 |
| Risperidone | 31 | $199 | $6 |
| Buspirone | 30 | $155 | $5 |
| Escitalopram | 22 | $146 | $7 |
| Trazodone | 22 | $126 | $6 |
| Quetiapine | 24 | $123 | $5 |
| Citalopram Hbr | 12 | $60 | $5 |
2018: 10 drugs
| Ingrezza | 13 | $81,830 | $6,295 |
| Abilify Maintena | 12 | $19,510 | $1,626 |
| Latuda | 15 | $18,612 | $1,241 |
| Quetiapine Fumarate Er | 11 | $1,882 | $171 |
| Sertraline | 120 | $812 | $7 |
| Risperidone | 48 | $650 | $14 |
| Mirtazapine | 34 | $555 | $16 |
| Bupropion Xl | 21 | $485 | $23 |
| Fluoxetine | 12 | $151 | $13 |
| Buspirone | 29 | $127 | $4 |
2017: 9 drugs
| Seroquel Xr | 13 | $8,690 | $668 |
| Aripiprazole | 12 | $2,812 | $234 |
| Sertraline | 111 | $645 | $6 |
| Risperidone | 54 | $438 | $8 |
| Mirtazapine | 40 | $402 | $10 |
| Bupropion Xl | 18 | $359 | $20 |
| Buspirone | 26 | $126 | $5 |
| Donepezil | 19 | $105 | $6 |
| Hydroxyzine Pamoate | 11 | $55 | $5 |
2016: 10 drugs
| Seroquel Xr | 22 | $14,182 | $645 |
| Aripiprazole | 19 | $5,202 | $274 |
| Sertraline | 104 | $538 | $5 |
| Mirtazapine | 27 | $362 | $13 |
| Risperidone | 29 | $230 | $8 |
| Bupropion Xl | 12 | $190 | $16 |
| Buspirone | 28 | $161 | $6 |
| Donepezil | 18 | $87 | $5 |
| Quetiapine | 11 | $71 | $6 |
| Citalopram Hbr | 11 | $51 | $5 |
2015: 4 drugs
| Pristiq Er | 11 | $4,159 | $378 |
| Sertraline | 59 | $267 | $5 |
| Mirtazapine | 25 | $249 | $10 |
| Risperidone | 23 | $125 | $5 |
2014: 7 drugs
| Abilify | 11 | $8,230 | $748 |
| Seroquel Xr | 13 | $4,783 | $368 |
| Sertraline | 52 | $465 | $9 |
| Mirtazapine | 21 | $336 | $16 |
| Risperidone | 13 | $135 | $10 |
| Buspirone | 16 | $116 | $7 |
| Zolpidem | 11 | $103 | $9 |
2013: 2 drugs
| Sertraline | 37 | $496 | $13 |
| Mirtazapine | 11 | $139 | $13 |
Money from drug and device companies
$1,563 in 2025
| 2025 | 10 | 41 | None | $1,563 |
| 2024 | 7 | 20 | None | $1,090 |
| 2023 | 8 | 15 | None | $1,009 |
| 2022 | 9 | 44 | None | $1,089 |
| 2021 | 6 | 11 | None | $483 |
| 2020 | 6 | 13 | None | $359 |
| 2019 | 10 | 39 | None | $1,344 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Cobenfy | $354 | 9 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $324 | 10 payments
|
| Teva Pharmaceuticals USA | Uzedy | $282 | 4 payments
|
| Alkermes | Lybalvi | $243 | 9 payments
|
| Axsome Therapeutics | Auvelity | $219 | 3 payments
|
| Otsuka America Pharmaceutical | Rexulti | $52 | 2 payments
|
See all 41 published payments
| Alkermes | Meals · 2025-11-20 | Aristada | $22 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-11-20 | Caplyta | $110 |
| Axsome Therapeutics | Meals · 2025-11-19 | Auvelity | $10 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-13 | Cobenfy | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-13 | Cobenfy | $2 |
| Alkermes | Meals · 2025-11-13 | Aristada | $11 |
| Alkermes | Meals · 2025-10-30 | Aristada | $7 |
| Janssen Pharmaceuticals | Meals · 2025-10-23 | Invega Sustenna | $17 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-10-08 | Caplyta | $10 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-24 | Cobenfy | $125 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-09-24 | Caplyta | $7 |
| Alkermes | Meals · 2025-09-18 | Aristada | $13 |
| Teva Pharmaceuticals USA | Meals · 2025-09-16 | Austedo Xr | $122 |
| Lundbeck | Meals · 2025-09-11 | Rexulti | $29 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-09-10 | Caplyta | $13 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-21 | Cobenfy | $1 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-21 | Cobenfy | $22 |
| Alkermes | Meals · 2025-08-21 | Aristada | $23 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-08-19 | Caplyta | $12 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-08 | Cobenfy | $3 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-08 | Cobenfy | $20 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-07-30 | Caplyta | $122 |
| Alkermes | Meals · 2025-07-24 | Aristada | $14 |
| Axsome Therapeutics | Meals · 2025-07-22 | Auvelity | $86 |
| Teva Pharmaceuticals USA | Meals · 2025-07-22 | Uzedy | $2 |
| Teva Pharmaceuticals USA | Meals · 2025-07-21 | Uzedy | $36 |
| Vanda Pharmaceuticals | Meals · 2025-07-09 | Fanapt | $29 |
| Alkermes | Meals · 2025-07-03 | Aristada | $11 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-03 | Caplyta | $11 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-05-21 | Caplyta | $8 |
| Teva Pharmaceuticals USA | Meals · 2025-05-15 | Uzedy | $122 |
| Otsuka America Pharmaceutical | Meals · 2025-04-24 | Abilify Asimtufii | $25 |
| Axsome Therapeutics | Meals · 2025-03-27 | Auvelity | $123 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-19 | None | $36 |
| Alkermes | Meals · 2025-03-18 | Lybalvi | $130 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-03-17 | Caplyta | $11 |
| Otsuka America Pharmaceutical | Meals · 2025-03-06 | Rexulti | $27 |
| Neurocrine BioSciences | Meals · 2025-02-17 | Ingrezza | $15 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-02-05 | Caplyta | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-16 | Cobenfy | $125 |
| Alkermes | Meals · 2025-01-08 | Aristada | $12 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,090
| Otsuka America Pharmaceutical | Abilify Maintena | $515 | 5 payments
|
| Alkermes | Lybalvi | $188 | 5 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $152 | 4 payments
|
| Axsome Therapeutics | Auvelity | $143 | 2 payments
|
| Abbvie | Vraylar | $41 | 2 payments
|
| Indivior | Perseris | $37 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $15 | 1 payment
|
2023: $1,009
| Otsuka America Pharmaceutical | Abilify Maintena | $395 | 4 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $359 | 4 payments
|
| BioXcel Therapeutics | Igalmi | $125 | 1 payment
|
| Indivior | Perseris | $48 | 2 payments
|
| Axsome Therapeutics | Auvelity | $28 | 1 payment
|
| Alkermes | Aristada | $21 | 1 payment
|
| AbbVie | Vraylar | $17 | 1 payment
|
| Iti | Caplyta | $14 | 1 payment
|
2022: $1,089
| Neurocrine Biosciences | Ingrezza | $320 | 9 payments
|
| Alkermes | Aristada | $251 | 8 payments
|
| Otsuka America Pharmaceutical | Rexulti | $125 | 1 payment
|
| Sunovion Pharmaceuticals | Latuda | $92 | 10 payments
|
| Iti | Caplyta | $81 | 5 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $76 | 4 payments
|
| Abbvie | Vraylar | $56 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $49 | 3 payments
|
| Indivior | Perseris | $39 | 2 payments
|
2021: $483
| Iti | Caplyta | $152 | 3 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $122 | 1 payment
|
| AbbVie | Vraylar | $108 | 2 payments
|
| Alkermes | Lybalvi | $58 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $27 | 2 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $17 | 1 payment
|
2020: $359
| Otsuka America Pharmaceutical | Rexulti | $122 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $60 | 3 payments
|
| Sunovion Pharmaceuticals | Latuda | $59 | 3 payments
|
| Lundbeck | Rexulti | $58 | 3 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $42 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $18 | 1 payment
|
2019: $1,344
| Otsuka America Pharmaceutical | Abilify Maintena | $422 | 10 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $302 | 7 payments
|
| Neurocrine Biosciences | Ingrezza | $190 | 6 payments
|
| Ironshore Pharmaceuticals | Jornay Pm 20mg Capsules (Bottle of 100) | $138 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $119 | 4 payments
|
| Lundbeck | Rexulti | $39 | 2 payments
|
| Allergan | Vraylar | $36 | 2 payments
|
| Sunovion Pharmaceuticals | Latuda | $34 | 2 payments
|
| Teva Pharmaceuticals USA | Austedo | $33 | 2 payments
|
| Alkermes | Aristada | $32 | 2 payments
|
Professional record
- NPI
- 1588776918
- Licence
- CA A86927California A86927: Current · expires 2027-11-30
- Group
- Mental Health Systems Inc · Bio-Behavioral Medical Clinics, Inc
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084P0804X (2084P0804X); Psychiatry (2084P0800X)
- Mailing address
- 10090 N Page Ave, Fresno, CA, 93720
- NPI first listed
- 2006-08-31
- NPI last updated
- 2024-09-10
- NPI record certified
- 2024-09-10
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1060 W Sierra Ave Ste 105, Fresno, CA, 93711 · 2549 W Shaw Ave, Fresno, CA, 93711
This office lists an electronic records connection.